Vifor Fresenius Medical Care Renal Pharma
- Business Wire
VFMCRP announces positive results of phase-III clinical trial of Velphoro® in China
Met primary efficacy endpoint of non-inferiority versus sevelamer carbonate Velphoro® effective in lowering and maintaining serum phosphorus level Safety profile…
Read More » - Business Wire
First patient enrolled in CARE-HK in HF to evaluate role of Veltassa® (patiromer) in enabling RAASi treatment
CARE-HK in heart failure (HF) is the first global registry of around 5,000 patients with chronic HF who have or…
Read More » - Business Wire
VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin
Companies have successfully submitted the EU regulatory application for marketing authorization for difelikefalin If approved, difelikefalin injection will be the…
Read More » - Health
VFMCRP and ChemoCentryx Provide Topline Results From ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)
St. Gallen, Switzerland & Mountain View, Calif., United States: As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal…
Read More » - Business
VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa® agreement
Bad Homburg, Germany & St. Gallen, Switzerland: Veltassa® is a well-tolerated1 and effective2 oral calcium potassium binder for the treatment of hyperkalemia supported…
Read More » - Business
Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications
St. Gallen, Switzerland & Uniondale, N.Y., United States: Vifor Pharma acquires a worldwide license, excluding Greater China, to late-stage product ANG-3777 ANG-3777 is…
Read More » - United States
VFMCRP and ChemoCentryx announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan
St. Gallen, Switzerland & Mountain View, Calif., United States: Companies have completed the EU regulatory application for marketing approval of…
Read More » -
Vifor Pharma and Cara Therapeutics sign US license agreement for i.v. Korsuva™* to treat dialysis patients with pruritus
St. Gallen, Switzerland & Stamford, Conn., United States: Vifor Pharma secures US commercial rights for i.v. Korsuva in non-Fresenius Medical…
Read More »